CN102089301A - 哌啶gpcr激动剂 - Google Patents

哌啶gpcr激动剂 Download PDF

Info

Publication number
CN102089301A
CN102089301A CN2009801269900A CN200980126990A CN102089301A CN 102089301 A CN102089301 A CN 102089301A CN 2009801269900 A CN2009801269900 A CN 2009801269900A CN 200980126990 A CN200980126990 A CN 200980126990A CN 102089301 A CN102089301 A CN 102089301A
Authority
CN
China
Prior art keywords
acceptable salt
pharmacy acceptable
compound
general formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801269900A
Other languages
English (en)
Chinese (zh)
Inventor
L·S·伯特伦
M·C·T·法伊夫
R·P·吉瓦兰特纳姆
J·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0812640A external-priority patent/GB0812640D0/en
Priority claimed from GB0902796A external-priority patent/GB0902796D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of CN102089301A publication Critical patent/CN102089301A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2009801269900A 2008-07-10 2009-07-10 哌啶gpcr激动剂 Pending CN102089301A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0812640A GB0812640D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812640.1 2008-07-10
GB0902796A GB0902796D0 (en) 2009-02-20 2009-02-20 Compounds
GB0902796.2 2009-02-20
PCT/GB2009/050826 WO2010004344A1 (en) 2008-07-10 2009-07-10 Piperidine gpcr agonists

Publications (1)

Publication Number Publication Date
CN102089301A true CN102089301A (zh) 2011-06-08

Family

ID=41077623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801269900A Pending CN102089301A (zh) 2008-07-10 2009-07-10 哌啶gpcr激动剂

Country Status (7)

Country Link
US (1) US20110230507A1 (https=)
EP (1) EP2321308B9 (https=)
JP (1) JP2011527332A (https=)
CN (1) CN102089301A (https=)
AT (1) ATE557024T1 (https=)
ES (1) ES2387865T3 (https=)
WO (1) WO2010004344A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
KR20130113948A (ko) 2010-05-17 2013-10-16 어레이 바이오파마 인크. Gpr119 조절제로서의 피페리디닐-치환된 락탐류
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2616074A1 (en) * 2010-09-17 2013-07-24 Array Biopharma, Inc. Piperidinyl-substituted lactams as gpr119 modulators
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
US8957062B2 (en) 2011-04-08 2015-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2720544B1 (en) 2011-06-16 2016-12-21 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
EP2771000B1 (en) 2011-10-24 2016-05-04 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013074388A1 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) * 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US6518423B1 (en) * 1996-08-09 2003-02-11 Eisai Co., Ltd. Benzopiperidine derivatives
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
GB0700122D0 (en) * 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
US20100048625A1 (en) * 2007-01-04 2010-02-25 Matthew Colin Thor Fyfe Piperidine gpcr agonists
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
US20110230507A1 (en) 2011-09-22
JP2011527332A (ja) 2011-10-27
HK1158192A1 (en) 2012-07-13
ES2387865T3 (es) 2012-10-03
ATE557024T1 (de) 2012-05-15
EP2321308A1 (en) 2011-05-18
EP2321308B9 (en) 2012-08-08
EP2321308B1 (en) 2012-05-09
WO2010004344A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CN102089301A (zh) 哌啶gpcr激动剂
US8173807B2 (en) Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists
EP2114935B1 (en) Piperidine gpcr agonists
EP2318399B1 (en) Piperidinyl gpcr agonists
EP2114931B1 (en) Piperidine gpcr agonists
US20110212939A1 (en) Heterocyclic GPCR Agonists
US20100048632A1 (en) Piperidine GPCR Agonists
US20100048625A1 (en) Piperidine gpcr agonists
US20110178054A1 (en) Heterocyclic GPCR Agonists
US20100048631A1 (en) Piperidine GPCR Agonists
HK1157329B (en) Piperidinyl gpcr agonists
HK1158192B (en) Piperidine gpcr agonists
HK1135704B (en) Piperidine gpcr agonists
CN101622250A (zh) 哌啶gpcr激动剂
CN101627037A (zh) 哌啶gpcr激动剂
HK1135705B (en) Piperidine gpcr agonists
HK1163680A (en) Piperidine gpcr agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110608

WD01 Invention patent application deemed withdrawn after publication